Telo Genomics Presents Genomic Profiles of Peripheral Blood Minimal Residual Disease Cells at the 67th American Society of Hematology Meeting
Toronto, Ontario--(Newsfile Corp. - December 11, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a leader in the development of diagnostic and prognostic tests for human disease through the analysis of telomeres, today announced that the company highlighted its approach to Multiple Myeloma (MM) Minimal Residual Disease (MRD) testing with a poster presentation during the 67th American Society of Hematology (ASH) Annual Meeting in Orlando, Florida. The poster presentation describes the initial clinical results of...
2025-12-11 4:00 PM EST
Telo Genomics to Present Groundbreaking Individual-Cell Risk Assessment MRD Technology at the Myeloma Canada MRD Implementation Summit 2025
Toronto, Ontario--(Newsfile Corp. - November 13, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) ("Telo" or the "Company"), a leader in diagnostic and prognostic innovation through its proprietary multi-factor telomere analytics, today announced that it will deliver an industry presentation at the 2025 Myeloma Canada MRD Testing Implementation Summit, taking place November 14–15.Dr. Yulia Shifrin, Laboratory Director at Telo Genomics, will highlight the Company's breakthrough Minimal Residual Disease ("MRD") technology. Her presentation will introduce initial clinical results demonstrating the...
2025-11-13 8:30 AM EST
American Society of Hematology Accepts Telo Genomics' Abstract for Presentation at its 2025 Meeting and Exposition
Toronto, Ontario--(Newsfile Corp. - October 9, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in the development of diagnostic and prognostic tests for human disease through its proprietary multi-factor analysis of telomeres, today announced that the American Society of Hematology ("ASH") has accepted Telo Genomics' abstract submission for a poster presentation during the upcoming 2025 Annual Meeting.Dr. Yulia Shifrin, Laboratory Director of Telo Genomics, will present the abstract. The contents of the abstract will...
2025-10-09 8:30 AM EDT
Telo Genomics Expands Operations with Relocation of Clinical Laboratories to New, Larger Toronto Facility and Provides Board Update
Toronto, Ontario--(Newsfile Corp. - September 30, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of telomeres, today announces the relocation and expansion of its clinical laboratories and offices from the MaRS startup incubation hub into a new, state-of-the-art clinical laboratory space in the Greater Toronto Area. The relocation reflects the Company's continued progress leading to an expanding volume...
2025-09-30 4:30 PM EDT
Telo Genomics Highlights New MRD Methodology at The 2025 International Myeloma Society Meeting
Toronto, Ontario--(Newsfile Corp. - September 19, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of telomeres, today announced that the company has presented a poster abstract on minimal residual disease ("MRD") during the 22nd International Myeloma Society Annual Meeting in Toronto, Canada.The abstract, titled "3D Telomere Profiling of MRD in Liquid Biopsy as a Predictive Marker of Disease...
2025-09-19 8:30 AM EDT
Telo Geonomics Announces Engagement of Investor Relations Service Provider
Vancouver, British Columbia--(Newsfile Corp. - September 8, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics") announces that it has engaged Hayden IR, LLC. ("Hayden"), a U.S.-based investor relations consulting firm, to enhance the Company's investor relations strategy by increasing awareness of the Company, its technologies, and its business prospects.On August 20, 2025, the Company entered into an investor relations services agreement with Hayden (the "Agreement") under which Hayden will provide Telo services including strategic investor...
2025-09-08 4:20 PM EDT
Telo Genomics to Present at the OTCQB Venture Virtual Investor Conference
Toronto, Ontario--(Newsfile Corp. - August 5, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a leader in the development of diagnostic and prognostic tests for human disease through the analysis of telomeres, today announced that it will present at the OTCQB Venture Virtual Investor Conference on August 7th, 2025.This will be a live, interactive online event where investors are invited to ask the company questions in real-time. Telo Genomics will be represented by Guido Baechler,...
2025-08-05 4:10 PM EDT
International Myeloma Society Accepts Telo Genomics' MRD Abstract for Presentation at Its 2025 Meeting
Toronto, Ontario--(Newsfile Corp. - July 24, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a leader in the development of diagnostic and prognostic tests for human disease through the analysis of telomeres, today announced that the International Myeloma Society ("IMS") has accepted Telo Genomics' abstract submission for a poster presentation on minimal residual disease ("MRD") during the upcoming 22nd International Myeloma Society Annual Meeting in Toronto, Canada.The new abstract titled, "3D Telomere Profiling of MRD...
2025-07-24 8:30 AM EDT
Telo Genomics Corp. to File Statement of Defence and Counterclaim to Lawsuit Filed by Former President
Toronto, Ontario--(Newsfile Corp. - June 30, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics") has received a Statement of Claim filed by Sherif Louis, the former President of the Company, in the amount of approximately $530,000 for notice and bonuses that he claims are owed to him. Telo intends to file a statement of defence and counterclaim and vigorously defend the claim. For further information, please contact:Guido BaechlerExecutive Chairman 647-477-9365info@telodx.com MaRS Centre, South Tower101...
2025-06-30 6:48 PM EDT
Telo Genomics Initiate Clinical Trial for Minimal Residual Disease in Multiple Myeloma
Toronto, Ontario--(Newsfile Corp. - June 18, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in the development of diagnostic and prognostic tests for human disease through its proprietary 3D analysis of the genomic instability of telomeres, is pleased to announce that it has initiated a multiple myeloma ("MM") clinical trial in collaboration with Cleveland Clinic Cancer Institute, Cleveland, OH. The samples are to be assessed and stratified between minimal residual disease ("MRD") patients...
2025-06-18 8:30 AM EDT
Telo Genomics Receives New Client Tier under Intellectual Property Ontario (IPON)
Toronto, Ontario--(Newsfile Corp. - May 27, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a leader in the development of diagnostic and prognostic tests for human disease through the analysis of telomeres, is pleased to announce that it has entered a new client agreement with Intellectual Property Ontario (IPON). IPON supports Ontario-based enterprises in securing and expanding their intellectual property (IP) portfolios. Telo announced on November 19, 2024, that it was accepted into the program...
2025-05-27 8:30 AM EDT
European Hematology Association Accepts Abstract from Telo Genomics for Presentation at The 2025 Congress
Toronto, Ontario--(Newsfile Corp. - May 15, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, today announced that the European Hematology Association ("EHA") has accepted Telo Genomics' abstract submission for a poster presentation during the upcoming EHA 2025 Congress.The new abstract is titled "Advanced Risk Prediction for Smoldering Multiple Myeloma ("SMM") Patients Through the Combination of Mayo...
2025-05-15 8:30 AM EDT
Telo Genomics Announces Acceptance of its MRD Validation Data in Multiple Myeloma for ASCO 2025
Toronto, Ontario--(Newsfile Corp. - April 10, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, today announced that the American Society of Clinical Oncology (ASCO) has accepted Telo Genomics' abstract submission regarding a concordance analysis between blood and marrow samples, using the TeloView® Minimal Residual Disease (MRD) methodology, as an online publication at the ASCO Annual Meeting.MRD...
2025-04-10 8:30 AM EDT
Telo Genomics Announces Appointment of John Farlinger to Its Board of Directors
Toronto, Ontario--(Newsfile Corp. - April 4, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics") a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, is pleased to announce that John Farlinger has joined the Company's Board of Directors. Mr. Farlinger will also serve as Chair of the Company's audit committee.Mr. Farlinger is a veteran venture and private equity backed executive and entrepreneur, bringing more than...
2025-04-04 8:30 AM EDT
Telo Genomics Appoints Baechler Executive Chairman of The Board of Directors
Toronto, Ontario--(Newsfile Corp. - March 12, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics") a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, is pleased to announce Mr. Guido Baechler, has assumed the role of Executive Chairman. In his expanded role, Mr. Baechler will provide more active strategic leadership, working closely with the company's founder Dr. Sabine Mai and with the executive team to...
2025-03-12 8:30 AM EDT
Telo Genomics Announces Expanded Partnership with Trusted Health Advisors
Toronto, Ontario--(Newsfile Corp. - February 27, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics") announces that, further to its engagement with Trusted Health Advisors ("THA"), as disclosed in a news release dated January 30, 2024, the Company has expanded and extended its agreement (the "Agreement") with THA. Under the new Agreement, THA will further support the partnering and commercialization of Telo's diagnostic technologies over a six-month term.The THA Partners, who are experts in diagnostic...
2025-02-27 8:30 AM EST
Telo Genomics Closes Oversubscribed $2.5 Million Private Placement
Toronto, Ontario--(Newsfile Corp. - December 23, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3DOA) (the "Company" or "Telo") is pleased to announce that, further to its news release dated December 12, 2024, it has closed an over-subscribed, non-brokered private placement of 25,459,000 units ("Units") at a price of $0.10 per Unit for gross proceeds of $2,545,900 (the "Offering").Each Unit consists of one common share of the Company (a "Common Share") and one non-transferable common share purchase warrant...
2024-12-23 4:00 PM EST
Telo Genomics Announces Private Placement for up to $2 Million
Toronto, Ontario--(Newsfile Corp. - December 12, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3DOA) (the "Company" or "Telo") is pleased to announce a non-brokered private placement of units ("Units") at a price of $0.10 per Unit for gross proceeds of up to $2,000,000 (the "Offering").Each Unit will consist of one common share of the Company (a "Common Share") and one non-transferable common share purchase warrant (a "Warrant"). Each Warrant will entitle the holder to acquire one additional...
2024-12-12 8:45 AM EST
Telo Genomics Receives Approval from the Intellectual Property Ontario Program (IPON)
Toronto, Ontario--(Newsfile Corp. - November 19, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that its application to the IPON program (Intellectual Property Ontario) was approved. The IPON program leverages the innovation of Ontario enterprises in securing and expanding their intellectual property (IP) portfolio. The program provides training, advisory services and...
2024-11-19 8:45 AM EST
Telo Genomics Expands its Strategic Collaboration with Mayo Clinic
Toronto, Ontario--(Newsfile Corp. - October 30, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that it has amended its agreement with Mayo Clinic, Rochester, Minnesota, US. The amendment is an extension of the Telo Genomics relationship with Mayo Clinic to include their participation in Telo's Physician Experience Program SMART, using the...
2024-10-30 8:45 AM EDT